^
Association details:
| Biomarker: | NTRK2 fusion |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
...Larotrectinib and entrectinib are treatment options for patients with hepatocellular carcinoma that is NTRK gene fusion positive.
Title:
New sarcoma drug approved for use in England
Excerpt:
We’re delighted to announce that a new drug, larotrectinib, has been approved for the treatment of certain sarcomas in England. ‘Sarcoma UK welcomes today’s approval of larotrectinib. Made available for use by the Cancer Drugs Fund and approved by NICE (National Institute for Health and Care Excellence) larotrectinib is a new type of ‘histologically-independent’ drug that targets tumours based on their genetic makeup. It works by targeting the specific NTKR genetic abnormality in tumours meaning patients are treated according to the genetics of their tumour rather than where it is in the body.
Source:
Title:
SO-29 Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive gastrointestinal cancer: An expanded dataset
Published date:
07/04/2021
Excerpt:
As of July 20, 2020, 18 patients with metastatic TRK fusion-positive GI cancer were enrolled...The other tumor types were cholangiocarcinoma (n=3), pancreatic (n=2), appendiceal (n=1), esophageal (n=1), and hepatocellular carcinoma (n=1)….In patients with TRK fusion-positive GI cancer, larotrectinib demonstrated rapid responses with high survival rates and a favorable safety profile.
DOI:
10.1016/j.annonc.2021.05.053
Trial ID:
